AU2016215087A1 - Tetra-specific, octameric binding agents and antibodies against Clostridium difficile toxin A and toxin B for treatment of C. difficile infection - Google Patents

Tetra-specific, octameric binding agents and antibodies against Clostridium difficile toxin A and toxin B for treatment of C. difficile infection Download PDF

Info

Publication number
AU2016215087A1
AU2016215087A1 AU2016215087A AU2016215087A AU2016215087A1 AU 2016215087 A1 AU2016215087 A1 AU 2016215087A1 AU 2016215087 A AU2016215087 A AU 2016215087A AU 2016215087 A AU2016215087 A AU 2016215087A AU 2016215087 A1 AU2016215087 A1 AU 2016215087A1
Authority
AU
Australia
Prior art keywords
binding agent
binding
vhh
peptide monomers
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016215087A
Other languages
English (en)
Inventor
Hanping Feng
Yongjun Guan
Lianfa SHI
Zhiyong Yang
Yongrong ZHANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland Baltimore
Original Assignee
University of Maryland Baltimore
University of Maryland College Park
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Maryland Baltimore, University of Maryland College Park filed Critical University of Maryland Baltimore
Publication of AU2016215087A1 publication Critical patent/AU2016215087A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016215087A 2015-02-06 2016-02-05 Tetra-specific, octameric binding agents and antibodies against Clostridium difficile toxin A and toxin B for treatment of C. difficile infection Abandoned AU2016215087A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562113046P 2015-02-06 2015-02-06
US62/113,046 2015-02-06
PCT/US2016/016852 WO2016127104A2 (en) 2015-02-06 2016-02-05 Tetra-specific, octameric binding agents and antibodies against clostridium difficile toxin a and toxin b for treatment of c. difficile infection

Publications (1)

Publication Number Publication Date
AU2016215087A1 true AU2016215087A1 (en) 2017-08-17

Family

ID=56564887

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016215087A Abandoned AU2016215087A1 (en) 2015-02-06 2016-02-05 Tetra-specific, octameric binding agents and antibodies against Clostridium difficile toxin A and toxin B for treatment of C. difficile infection

Country Status (6)

Country Link
US (1) US10961299B2 (https=)
EP (1) EP3253790A4 (https=)
JP (2) JP6640232B2 (https=)
AU (1) AU2016215087A1 (https=)
CA (1) CA2974720A1 (https=)
WO (1) WO2016127104A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
JP7184336B2 (ja) 2015-10-13 2022-12-06 ザ ユニバーシティ オブ メリーランド，ボルチモア クロストリジウム・ディフィシル感染症に対する酵母ベースの免疫療法
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US20200157224A1 (en) * 2017-06-25 2020-05-21 Systimmune, Inc. Multi-specific antibodies and methods of making and using thereof
KR102763369B1 (ko) * 2017-06-25 2025-02-05 시스트이뮨, 인코포레이티드 다중-특이적 항체 및 이를 제조하는 방법 및 이의 용도
AU2020287324A1 (en) * 2019-06-03 2022-01-20 Fzata, Inc. Humanized tetra-specific octavalent antibody against Clostridium difficile toxin A and B
CA3193741A1 (en) * 2020-09-02 2022-03-10 The Regents Of The University Of California A broadly neutralizing molecule against clostridium difficile toxin b

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006323412A1 (en) * 2005-12-06 2007-06-14 Domantis Limited Ligands that have binding specificity for EGFR and/or VEGF and methods of use therefor
US9023352B2 (en) * 2007-02-20 2015-05-05 Tufts University Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
US20160031971A9 (en) * 2007-02-20 2016-02-04 Tufts University Methods and compositions with a recombinant neutralizing binding protein for treating toxin exposure
KR20100052545A (ko) 2007-08-28 2010-05-19 바이오겐 아이덱 엠에이 인코포레이티드 Ｉｇｆ―１ｒ의 다중 에피토프에 결합하는 조성물
NZ601117A (en) 2010-03-03 2014-06-27 Boehringer Ingelheim Int Biparatopic abeta binding polypeptides
US8702942B2 (en) 2010-12-17 2014-04-22 Malvern Instruments, Ltd. Laser doppler electrophoresis using a diffusion barrier
EP2961770A1 (en) 2013-02-26 2016-01-06 Roche Glycart AG Bispecific t cell activating antigen binding molecules
US11634502B2 (en) * 2013-03-15 2023-04-25 Amgen Inc. Heterodimeric bispecific antibodies
JP7184336B2 (ja) * 2015-10-13 2022-12-06 ザ ユニバーシティ オブ メリーランド，ボルチモア クロストリジウム・ディフィシル感染症に対する酵母ベースの免疫療法

Also Published As

Publication number Publication date
WO2016127104A2 (en) 2016-08-11
US10961299B2 (en) 2021-03-30
US20180244760A1 (en) 2018-08-30
EP3253790A4 (en) 2018-07-25
CA2974720A1 (en) 2016-08-11
JP6640232B2 (ja) 2020-02-05
JP2018506972A (ja) 2018-03-15
WO2016127104A3 (en) 2016-10-27
JP2020072685A (ja) 2020-05-14
EP3253790A2 (en) 2017-12-13

Similar Documents

Publication Publication Date Title
US10961299B2 (en) Tetra-specific, octameric binding agents and antibodies against Clostridium difficile toxin A and toxin B for treatment of C. difficile infection
CA3091639C (en) Anti-tigit antibodies and uses thereof
CN101939337B (zh) 抗trka抗体及其衍生物
US20180106790A1 (en) Single chain proteins with c-terminal modifications
KR20100021577A (ko) 에스.아우레우스 ＯＲＦ0657ｎ을 표적화하는 항원 결합 단백질
RS56814B1 (sr) Varijante anti-tfpi antitela sa diferencijalnim vezivanjem duž ph opsega zarad poboljšanja farmakokinetike
RS60920B1 (sr) Kombinovane terapije primenom anti-pseudomonas psl i pcrv vezujućih molekula
CA3001863A1 (en) Yeast-based immunotherapy against clostridium difficile infection
US20120269822A1 (en) Anti-Botulinum Neurotoxin a Single Domain Antibody Antibodies
CN106164094B (zh) 双特异性抗原结合多肽
CN113166248B (zh) 人源化抗人ox40单克隆抗体及其制备方法和用途
Péchiné et al. Emerging monoclonal antibodies against Clostridium difficile infection
CN113416249B (zh) 针对破伤风毒素的组合物
CN113444172A (zh) 金黄色葡萄球菌α-毒素特异性抗体及其应用
EP4286409A1 (en) Antigen-binding protein targeting staphylococcus aureus ?-hemolysis and application thereof
US12077575B2 (en) Humanized tetra-specific octavalent antibody against clostridium difficile toxin A and B
CN114957460A (zh) 交叉中和金黄色葡萄球菌毒素的抗原结合蛋白及其用途
US20250059295A1 (en) Steap2 directed t-cell engagers and compositions thereof
Mukherjee et al. Intramuscular delivery of formulated RNA encoding six linked single-domain antibodies is highly protective for exposures to three Botulinum neurotoxin serotypes
WO2024119065A9 (en) Anti-mesothelin bispecific antibodies and methods of use
US9732145B2 (en) Antibodies directed to Bacillus anthracis protective antigen
HK40089099A (en) Anti-tigit antibody and double antibody and their application
CN114901695A (zh) 抗gitr抗体及其用途

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application